Rare drug Ultomiris posts KRW 40 billion in sales in 3 yrs
By Nho, Byung Chul | translator Kim, Jung-Ju
24.03.05 05:50:42
가나다라
0
Soliris follow-on drug… improved convenience in intake from ‘every 2 weeks →8 weeks’
Posts sales of KRW 19.5 billion, KRW 43.1 billion, and KRW 37.8 billion by Q3 in 2021,2022,2023, respectively
Costs KRW 5,598,942 per 30ml vial…offers financial savings over existing drugs
Becoming a KRW 40 billion blockbuster in just 3 years since its launch, the growth potential of AstraZeneca’s Ultomiris Inj (ravulizumab) is gaining industry-wide attention.
The biological orphan drug Ultomiris Inj. is considered to be the successor to Soliris Inj. (eculizumab) with significant improvements in dosing convenience.
The drug was approved in June 2021 at a reimbursed price of KRW 5,598,942 for the 30 ml vial and is indicated for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome.
By Q3 2021, 2022, 2023, Ultomiris has generated sales of KRW 19.5 billion, KRW 43.1 billion, and KRW 37.8 billion, respectively.
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)